Medical Condition

congenital heart disease

Total Trials

21

Recruiting Now

21

Trial Phases

Phase 3, Phase 1, Phase 2

Cardiovascular disease trials address coronary artery disease, heart failure, atrial fibrillation, and acute coronary syndromes — collectively the leading cause of mortality globally. After decades of incremental improvement in lipid-lowering and antithrombotic therapy, the field is now exploring RNA-based therapies, gene editing, and cardiac regeneration approaches.

Active research includes PCSK9 inhibitors and inclisiran for LDL reduction, SGLT2 inhibitors in heart failure with preserved ejection fraction (HFpEF), mavacamten for hypertrophic cardiomyopathy, cardiac stem cell therapies, and AI-guided device therapies. Wearables and remote monitoring are also being validated as clinical endpoints.

Enrollment eligibility typically depends on left ventricular ejection fraction (LVEF), NT-proBNP levels, and prior cardiovascular events.

Frequently Asked Questions — congenital heart disease Clinical Trials

How many clinical trials are currently recruiting for congenital heart disease?

ClinicalMetric currently tracks 21 actively recruiting clinical trials for congenital heart disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 21. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for congenital heart disease?

congenital heart disease research spans Phase 1 (1 trial), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a congenital heart disease clinical trial?

Eligibility criteria for congenital heart disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Boston Children's Hospital 2 trials

Mingtao Zhao 1 trial

Children's Hospital of Fudan University 1 trial

Medical University of Vienna 1 trial

Sun Yat-sen University 1 trial

congenital heart disease

Frequently Asked Questions — congenital heart disease Clinical Trials

Recruiting Clinical Trials

IPSC Repository of Pediatric Cardiovascular Disease

Application of Ultrasound Technique in Locating the End of the Gastric Tube in Children Aged 0-6 Years

Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation

Atrial Late Gadolinium Enhancement in Patients with Repaired Congenital Heart Disease

Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

Copenhagen Baby Heart Study - Impact

Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment

Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis

Effect of Sacubitril-Valsartan on Cardiac Structure and Function

The Co-Op @ HeartWorks

Fontan Fitness Trial

Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD)

Propranolol Treatment for Postoperative Chylothorax

Swiss National Registry of Adults With Congenital Heart Disease

iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease

Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents

HFNC vs NIPPV Following Extubation

Improving Congenital Heart Disease Care

The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)

A Comprehensive Registry Study of the Whole Life Cycle of Patients With CHD